Clinical trial
Bleomycin Electrosclerotherapy (BEST) for Slow-flow Vascular Malformations
NCT07720570 is registered in ClinicalTrials.gov with Rigshospitalet, Denmark as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Bleomycin Electrosclerotherapy (BEST) for Slow-flow Vascular Malformations
- Lead sponsor
- Rigshospitalet, Denmark
- Phase
- Observational
- Overall status
- Enrolling by invitation
- Start date
- August 31, 2026
- Completion date
- September 30, 2027
- Enrollment
- 60 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.